The scientific community affirmed that IL-6 is the main factor in the inflammatory process of large-vessel vasculitis, and case series have revealed that the humanized monoclonal antibody tocilizumab, which blocks the soluble IL-6 receptor, can produce clinical responses and have a steroid-sparing effect in cases with refractory TA, including patients refractory to anti-TNF (Nakaoka et al., 2018[175]). The gene discussed is IL6; the disease is Takayasu arteritis.